Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
[C-11]Methylreboxetine PET in Multiple Sclerosis
NCT03207464Phase 2Recruiting
- Sponsor
- Brigham and Women's Hospital
- Start
- Oct 2017
- Primary completion
- Dec 2026
- Countries
- 1
01
Overview
A Phase 2 trial of 11C-methylreboxetine in multiple sclerosis (MS), sponsored by Brigham and Women's Hospital. Started Oct 2017; status: recruiting.
02
Drugs
11C-methylreboxetine
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT03207464.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03207464.